Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients
US8609821B2 · kind B2 · utility
1Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2006 |
| Grant date | Dec 17, 2013 |
| Priority date | — |
| Expiry date | Mar 31, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2), in particular the monoclonal antibody Aprily-2, hybridoma cells producing monoclonal antibody Aprily-2, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2 in the diagnosis of B cell lymphoma resistance to treatment and the prognosis of clinical development of Diffuse Large B-Cell (DLBCL) lymphoma from high risk patients (>60 years and International Prognostic Index >2). An amino acid sequence GTGGPSQNGEGYP called Stalk, useful in the preparation of antibodies, is described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.